Fluticasone furoate

From Wikipedia, the free encyclopedia - View original article

Fluticasone furoate
Fluticasone furoate.svg
Systematic (IUPAC) name
(6α,11β,16α,17α)-6,9-difluoro-17-{[(fluoro-methyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate
Clinical data
AHFS/Drugs.comInternational Drug Names
Pregnancy cat.
  • C for Intranasal
Legal status
RoutesIntranasal
Pharmacokinetic data
Bioavailability0.51% (Intranasal)
Protein binding91%
MetabolismIntranasal
Hepatic (CYP3A4-mediated)
Half-life10 hours
ExcretionRenal
Identifiers
CAS number80474-14-2
ATC codeR01AD12
PubChemCID 9854489
DrugBankDB00588
ChemSpider8030195
UNIIJS86977WNV YesY
ChEBICHEBI:74899
ChEMBLCHEMBL1676
Chemical data
FormulaC27H29F3O6S 
Mol. mass538.576 g/mol
 
Jump to: navigation, search
Fluticasone furoate
Fluticasone furoate.svg
Systematic (IUPAC) name
(6α,11β,16α,17α)-6,9-difluoro-17-{[(fluoro-methyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate
Clinical data
AHFS/Drugs.comInternational Drug Names
Pregnancy cat.
  • C for Intranasal
Legal status
RoutesIntranasal
Pharmacokinetic data
Bioavailability0.51% (Intranasal)
Protein binding91%
MetabolismIntranasal
Hepatic (CYP3A4-mediated)
Half-life10 hours
ExcretionRenal
Identifiers
CAS number80474-14-2
ATC codeR01AD12
PubChemCID 9854489
DrugBankDB00588
ChemSpider8030195
UNIIJS86977WNV YesY
ChEBICHEBI:74899
ChEMBLCHEMBL1676
Chemical data
FormulaC27H29F3O6S 
Mol. mass538.576 g/mol

Fluticasone furoate is a synthetic corticosteroid derived from fluticasone, marketed by GlaxoSmithKline as Veramyst (US) and Avamys (Australia, Canada, EU, South Africa, Mexico, and Israel) for the treatment of allergic rhinitis. It is marketed under the name "Furamist" in India by Cipla. In India it is also marketed by Dr Reddys under the trade name 'Ennhale'. It can be administered by a nasal spray.[1]

The combination drug fluticasone furoate/vilanterol is approved for use in the United States by the Food and Drug Administration for long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.[2]

See also[edit]

References[edit]